Europe Bioproduction Market

The Europe bioproduction market was valued at US$ 5,515.06 million in 2022 and is expected to reach US$ 14,789.80 million by 2030; it is estimated to register a CAGR of 13.1% from 2022 to 2030. 

Increasing Prevalence of Chronic Diseases Drives Europe Bioproduction Market

Cardiovascular diseases (CVDs), neurological disorders, autoimmune disorders, and cancer are among the chronic diseases causing death and disabilities at a significant rate worldwide. As per the World Health Organization (WHO), CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Cancer is also among the leading causes of mortality worldwide, affecting a huge population; therefore, it acts as a huge financial burden on society. According to the WHO, in 2020, ~10 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively affecting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis' Kymriah is used to treat diffuse large B-cell lymphoma. 

Moreover, recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling the demand for biosimilars. In addition, biosimilars help improve life of millions of patients while saving billions of dollars of the healthcare system per year. They are effective and cost-effective options in treating many diseases, including chronic skin conditions and bowel diseases such as Crohn's disease, psoriasis, irritable bowel syndrome, and colitis; diabetes; autoimmune disease; cancer; kidney conditions; and arthritis. 

As the prevalence of chronic diseases is increasing at a high rate, the demand for bioproduction in treating life-threatening illnesses has progressed rapidly over the last five years, thereby driving the bioproduction market.

Europe Bioproduction Market Overview

The Europe bioproduction market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global bioproduction market and is estimated to register a notable CAGR during 2022-2030. The increasing prevalence of chronic disorders has resulted in a growing number of product launches and approvals, along with technological advancements and investment, thereby contributing to the market growth in the region.

Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare industry. Healthcare professionals can treat more patients with high-quality biologics at reduced cost. Due to the massive potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As a few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. In addition, healthcare providers such as PHI Orthopedic Physiotherapy Center, German International Clinic, Frankfurt, Germany; CBC Health Munich, Germany; and other providers offer stem cell therapy for various chronic diseases such as diabetic retinopathy, optic nerve neuritis, and rheumatoid arthritis. This is expected to increase the adoption of cell therapies in the coming years. Also, a growing number of partnerships among international players boost the market growth. For instance, in November 2020, Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including expanded commercial drug product manufacturing capacity in Europe for ZYNTEGLO, a one-time gene therapy for transfusion-dependent β-thalassemia (TDT). Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to flourish.

Europe Bioproduction Market Revenue and Forecast to 2030 (US$ Million)

Europe Bioproduction Strategic Insights

Strategic insights for the Europe Bioproduction provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Bioproduction Report Scope

Europe Bioproduction Regional Insights

The geographic scope of the Europe Bioproduction refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Bioproduction Market Segmentation 

The Europe bioproduction market is categorized into product, application, equipment, end user, and country. 

Based on product, the Europe bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest Europe bioproduction market share in 2022. 

In terms of application, the Europe bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest Europe bioproduction market share in 2022.

By equipment, the Europe bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest Europe bioproduction market share in 2022. 

In terms of end user, the Europe bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest Europe bioproduction market share in 2022. 

By country, the Europe bioproduction market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe bioproduction market share in 2022. 

Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc. are some of the leading companies operating in the Europe bioproduction market.